The association between diabetes and cancer was first noted over 100 years ago, but physicians have become increasingly aware of this association only in the last few years as recent studies have demonstrated that having diabetes increases the risk of almost all types of cancer. The risk of pancreatic, liver, and endometrial cancer is approximately twice that of the non-diabetic population. Some studies have reported a similar increase in the risk of bladder cancer and in cancers of the oral cavity.
Category: Products & Tech
ClimaPak uses an electrical charge to direct thermal energy away or towards the insulin stored inside...
Sanofi US announced that the iBGStar Blood Glucose Monitoring System
The results of a randomized clinical trial funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in children with type 2 diabetes show that children and adolescents treated with a combination of metformin and Avandia (rosiglitazone) had better glycemic control than children....
The FDA has issued a complete response letter to Japanese drug-maker Takeda Pharmaceutical regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone...
JDRF and Dexcom announced that they have formed a partnership whose goal is to accelerate the development of a novel wireless “smart transmitter” that would allow a continuous glucose monitor (CGM) system to communicate directly with an artificial pancreas...
Novo Nordisk’s widely popular GLP-1 analog Victoza made headlines at the beginning of the year when celebrity chef Paula Deen became a spokesperson…
Two new phase 3 studies published in The Lancet show that ultra long acting insulin, Degludec, an investigational compound from Novo Nordisk, significantly reduces the rates of nocturnal hypoglycemia by 25%, compared to insulin glargine.
The two studies included in total 1,635 participants and investigated insulin degludec compared to insulin...
Kamada, announced positive preliminary interim results from a Phase I/II clinical trial of D1-AAT, which includes the Alpha 1 protein, for the treatment of type 1 diabetes. D1-AAT may slow the progression of the type 1 diabetes, and may greatly reduce or eliminate, the need for insulin...
Biodel Inc. announced positive top-line results from a Phase 1 clinical trial of its product candidates, BIOD-123 and BIOD-125 -- two proprietary ultra rapid acting formulations of recombinant human insulin (RHI). The objective of the trial was to identify...